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Background: To give an overview on implant survival rates in patients with oral manifestations of systemic auto-
immune (oral Lichen planus (oLp), Pemphigus (Pe)), muco-cutaneous (Epidermolysis bullosa (EB)), autoimmune 
multisystemic rheumatic diseases (Sjögren ś syndrome (SjS), systemic Lupus erythematosus (sLE), or systemic 
Sclerosis (sSc)). 
Material and Methods: Systematic literature review (PubMed/Medline, Embase) using MESH and search term 
combinations, published between 1980 and August 2018 in English language reporting on dental implant-pros-
thetic rehabilitation of patients with oLp, Pe, EB, SjS, sLE, sSc, study design, age, gender, follow-up period (≥ 
12 months), implant survival rate. Implant-related weighed mean values of implant survival rate (wmSR) were 
calculated.  
Results: After a mean follow-up period (mfp) of 44.6 months, a wmSR of 98.3 % was calculated from data pub-
lished for patients with oLp (100 patients with 302 implants). Data of 27 patients (152 implants) with EB revealed 
wmSR of 98.7 % following mfp of 32.6 months. For 71 patients (272 implants) with SjS, wmSR was 94.2 % follow-
ing a mfp of 45.2 months, and for 6 patients (44 implants) with sSc, wmSR was 97.7 % after mfp of 37.5 months. 
One case report on one patient each with Pe (two implants) as well as sLE (6 implants) showed 100 % SR following 
at least 24 months. 
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Introduction
Survival and success rates of implant-prosthodontic re-
habilitations in patients without compromised general 
health conditions have been reported remarkably high 
even in mid- and long-term observations, after follow-
up periods of up to 10 or exceeding 10 years (1).
Although several conditions still are considered risk 
factors for dental implant prognosis in medically com-
promised patients, there are only few absolute contrain-
dications for this treatment option. Thus, disease con-
trol of conditions increasing the risk, and individualized 
risk-benefit assessment prior to dental implant therapy 
may be considered more important than the disorder or 
risky condition itself (2). However, dental implant ther-
apy is a viable treatment option even in these patients, 
revealing satisfying success rates of implant-borne 
prosthodontic treatment, suggesting that these patients 
might have a benefit from this treatment option. More-
over, these results encourage to overcome limitations of 
indications for dental implant treatment under reason-
able and careful stepwise treatment regimen as there 
are interdisciplinary approach, full therapy adherence 
by the patients as well as strict conditions of tight recall 
intervals. 
Oral manifestations of certain non-infectious systemic 
diseases – among them autoimmune,  ulcerative, bul-
lous, or fibrous – are frequently aggravated by second-
ary effects of the underlying pathosis in patients suf-
fering from oral Lichen planus (oLp), pemphigus (Pe), 
Epidermolysis bullosa (EB), Sjögren ś syndrome (SjS), 
systemic Lupus erythematosus (sLE), or systemic scle-
rosis (sSc).
These patients suffer from inflammatory, ulcerous, ero-
sive lesions, sicca symptoms, scar formation, or limita-
tion of mouth opening. Secondary effects of these diseas-
es are compromised eating and swallowing, xerostomia, 
enhanced risk of caries and periodontitis decay, alveolar 
ridge atrophy, scar tissue formation, enhanced risk of 
oral squamous cell carcinoma, and comprise side effects 
of systemic anti-inflammatory or immune-modulating 
medication. Thus, all these patients have in common a 
significant reduction of quality of life. Moreover, oral 
hygiene, dental treatment interventions and especially 
wearing mucosal-borne dentures are impeded. There-
fore, the question arises, if these patients might benefit 
Conclusions: Guidelines regarding implant treatment of patients with oLp, Pe, EB, SjS, sLE or sSc do not exist nor 
are contraindicating conditions defined. Implant survival rates of patients affected are comparable to those of healthy 
patients. For implant-prosthetic rehabilitation of patients with Pe and sLE no conclusions can be drawn due to lack 
of sufficient clinical data. Implant-prosthetic treatment guidelines regarding healthy patients should be strictly fol-
lowed, but frequent recall is recommended in patients affected with oLp, SjS, EB, SSc, Pe or sLE.
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from implant-borne prostheses, to avoid extensive con-
tact between prostheses and the oral mucosa.    
The aim of this systematic review of the literature was 
to reveal, if implant prosthetic treatment of patients suf-
fering from oLp, Pe, EB, SjS, sLE or sSc can be consid-
ered a promising treatment option. 
Material and Methods
The focused question was: which implant survival rates 
were reported in patients suffering from mucocutane-
ous or autoinflammatory diseases oLp, Pe, EB, SjS, sLE 
or sSc? 
A systematic literature search was performed, using 
electronic literature databases (PubMed/Medline, Em-
base) and MESH and search term combinations (see 
Table 1). The systematic review of the literature was 
done related to the PICO format. Publications report-
ing on patients suffering from oLp, Pe, EB, SjS, sLE or 
sSc (population), undergoing clinical use of dental im-
plant-prosthetic rehabilitation (intervention) and reveal-
ing study design, age, gender, number of patients and 
implants, follow-up period of or exceeding 12 months 
and implant survival rate (outcome), and published be-
tween 1980 and December 2017 in English or German 
language were included. A control group was lacking in 
most of publications. Publications were excluded, if for-
mation of malignant tumour in the head and neck region 
interfered with implant or patient survival. 
Publications were identified and abstracts were evalu-
ated independently by two reviewers (FPS and AMSW) 
by formal consideration of inclusion criteria and due to 
content matching the search purposes. Agreement of 
inclusion or exclusion of publications by two review-
ers was expressed by calculation of the κ-value. After 
reaching full consent between the reviewers regarding 
the screening of abstracts, publications were selected 
for inclusion into further analysis.
Data reporting on implant survival, patients and im-
plants numbers and duration of observational periods 
were retrieved from included publications. Weighed 
mean values of age (patient-related) and of implant-
related implant survival rate (wmSR) and observational 
periods (mOP) were calculated. 
For meta-analysis funnel and forest plots for all publica-
tions and for the subgroups of publications with data 






initial search to determine start 
point of literature search 
(osseointegrated[All Fields] AND implant[All Fields]) AND ("survival"[All Fields] OR 





MeSH and search term combinations 
oLp ("lichen planus, oral"[MeSH Terms] OR ("lichen"[All Fields] AND "planus"[All Fields] AND 
"oral"[All Fields]) OR "oral lichen planus"[All Fields] OR ("oral"[All Fields] AND "lichen"[All 
Fields] AND "planus"[All Fields])) AND ("dental implants"[MeSH Terms] OR ("dental"[All 
Fields] AND "implants"[All Fields]) OR "dental implants"[All Fields] OR ("dental"[All Fields] 
AND "implant"[All Fields]) OR "dental implant"[All Fields]) 
Pe ("dental implants"[MeSH Terms] OR ("dental"[All Fields] AND "implants"[All Fields]) OR 
"dental implants"[All Fields] OR ("dental"[All Fields] AND "implant"[All Fields]) OR "dental 
implant"[All Fields]) AND ("pemphigus"[MeSH Terms] OR "pemphigus"[All Fields]) 
("dental implants"[MeSH Terms] OR ("dental"[All Fields] AND "implants"[All Fields]) OR 
"dental implants"[All Fields] OR ("dental"[All Fields] AND "implant"[All Fields]) OR "dental 
implant"[All Fields]) AND ("pemphigoid, bullous"[MeSH Terms] OR ("pemphigoid"[All Fields] 
AND "bullous"[All Fields]) OR "bullous pemphigoid"[All Fields] OR "pemphigoid"[All Fields]) 
EB ("dental implants"[MeSH Terms] OR ("dental"[All Fields] AND "implants"[All Fields]) OR 
"dental implants"[All Fields] OR ("dental"[All Fields] AND "implant"[All Fields]) OR "dental 
implant"[All Fields]) AND ("epidermolysis bullosa"[MeSH Terms] OR ("epidermolysis"[All 
Fields] AND "bullosa"[All Fields]) OR "epidermolysis bullosa"[All Fields]) 
SjS ("dental implants"[MeSH Terms] OR ("dental"[All Fields] AND "implants"[All Fields]) OR 
"dental implants"[All Fields] OR ("dental"[All Fields] AND "implant"[All Fields]) OR "dental 
implant"[All Fields]) AND Sjogren[All Fields] 
sLE "dental implants"[MeSH Terms] OR ("dental"[All Fields] AND "implants"[All Fields]) OR "dental 
implants"[All Fields] OR ("dental"[All Fields] AND "implant"[All Fields]) OR "dental 
implant"[All Fields]) AND (lupus erythemateux[All Fields] OR lupus erythemathosus[All Fields] 
OR lupus erythematodes[All Fields] OR lupus erythematodus[All Fields] OR lupus 
erythematoses[All Fields] OR lupus erythematosis[All Fields] OR lupus erythematosous[All 
Fields] OR lupus erythematosus[All Fields] OR lupus erythematosus,[All Fields] OR lupus 
erythematosys[All Fields] OR lupus erythematous[All Fields] OR lupus erythematousus[All 
Fields]) 
sSc ("dental implants"[MeSH Terms] OR ("dental"[All Fields] AND "implants"[All Fields]) OR 
"dental implants"[All Fields] OR ("dental"[All Fields] AND "implant"[All Fields]) OR "dental 
implant"[All Fields]) AND ("scleroderma, systemic"[MeSH Terms] OR ("scleroderma"[All Fields] 
AND "systemic"[All Fields]) OR "systemic scleroderma"[All Fields] OR "scleroderma"[All 
Fields] OR "scleroderma, localized"[MeSH Terms] OR ("scleroderma"[All Fields] AND 
"localized"[All Fields]) OR "localized scleroderma"[All Fields]) 
("dental implants"[MeSH Terms] OR ("dental"[All Fields] AND "implants"[All Fields]) OR 
"dental implants"[All Fields] OR ("dental"[All Fields] AND "implant"[All Fields]) OR "dental 
implant"[All Fields]) AND ("scleroderma, systemic"[MeSH Terms] OR ("scleroderma"[All Fields] 
AND "systemic"[All Fields]) OR "systemic scleroderma"[All Fields] OR ("systemic"[All Fields] 
AND "sclerosis"[All Fields]) OR "systemic sclerosis"[All Fields]) 
Table 1. MeSH and search term combinations of literature search utilizing electronic databases.
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regarding oLp, SjS, EB, and sSc were created. The fun-
nel plot revealed that there is no evidence for publica-
tion bias if four publications were excluded from meta-
analysis. Forest plots showed 95% confidence intervals 
for the pooled implant failure rate per year and for the 
failure rate of each study. Moreover, I2 (measure for het-
erogeneity) was calculated for each meta-analysis. 
The statistical analysis was carried out using SPSS 22.0, 
R version 3.4.3 and the R package “meta”. 
Table 2, 2 continue, 2 continue-1 contains the PRISMA 
checklist regarding the methodology of the systematic 
review process and data analyses.  
Section / topic checklist item reported on 
page
1    title Implants in patients with oral manifestations of autoimmune or muco-cutaneous diseases 
– a systematic review
1
2    abstract
      structured 
      summary
Aim: To give an overview on implant survival rates in patients with oral manifestations 
of systemic autoimmune (oral Lichen planus (oLp), Pemphigus (Pe)), muco-cutaneous 
(Epidermolysis bullosa (EB)), or autoimmune multisystemic rheumatic diseases (Sjögren ś 
syndrome (SjS), systemic Lupus erythemathosus (sLE), or systemic Sclerosis (sSc)). Mate-
rial and Methods: Systematic literature review (PubMed/Medline, Embase) using MESH 
and search term combinations, published between 1980 and October 2017 in English or 
German language reporting on dental implant-prosthetic rehabilitation of patients with 
oLp, Pe, EB, SjS, sLE, sSc, study design, age, gender, follow-up period of or exceeding 12 
months and implant survival rate. Weighed mean values of implant survival rate (wmSR) 
were calculated for patients with oLp, Pe, EB, SjS, sLE or sSc. Results: After a mean 
follow-up period (mfp) of 44.6 months, a wmSR of 98.3 % was calculated from data pub-
lished for patients with oLp (100 patients with 302 implants). Data of 27 patients (152 im-
plants) with EB revealed wmSR of 98.7 % following mfp of 32.6 months. For 71 patients 
(272 implants) with SjS, wmSR was 94.2 % following a mfp of 45.2 months, and for 6 
patients (44 implants) with sSc, wmSR was 97.7 % after mfp of 37.5 months. One case re-
port on one patient each with Pe (two implants) as well as sLE (6 implants) showed 100 % 
SR following at least 24 months. Summary: Implant survival rates of patients with oLp, 
Pe, EB, SjS, sLE or sSc are comparable to those of healthy patients. For implant-prosthetic 
rehabilitation of patients with Pe and sLE no conclusions can be drawn due to lack of suf-
ficient clinical data. Implant-prosthetic treatment guidelines regarding healthy patients 
should be strictly followed, but frequent recall is recommended in patients affected with 
oLp, SjS, EB, SSc, Pe or sLE.
Since the systematic review was not registered, no registration number is available.
2
3    introduction  
      rationale
Since no guidelines regarding implant treatment of patients with oLp, Pe, EB, SjS, sLE 
or sSc exist nor are contraindications defined, the aim of this systematic review of the 
literature was to reveal, whether patients suffering from above mentioned diseases might 
benefit from implant-prosthodontic rehabilitation.
3
4    objectives Which implant survival rates were reported in patients suffering from mucocutaneous or 
autoinflammatory diseases oLp, Pe, EB, SjS, sLE or sSc?
PICO:  patients suffering from oLp, Pe, EB, SjS, sLE or sSc (population); clinical use of 
dental implant-prosthodontic rehabilitation (intervention); control groups were lacking; 
implant survival rate (outcome)
3, 4
5    methods  
      protocol and
      registration
A systematic literature search using MESH- and search term combinations (see Table 1) 
was performed to identify publications meeting the inclusion criteria.
This systematic review was not registered in any database.
4
6    eligibility 
      criteria
Inclusion of publications reporting on patients with oLp, Pe, EB, SjS, sLE or sSc (popula-
tion), undergoing clinical use of dental implant-prosthetic rehabilitation (intervention) and 
revealing study design, age, gender, number of patients and implants, follow-up period of 
or exceeding 12 months and implant survival rate (outcome); publication between 1980 
and October 2017 in English or German language; reporting on comparison of implant 
survival rates between healthy and affected patients.
Exclusion of publications, if not meeting the inclusion criteria, or if formation of malig-
nant tumour in the head and neck region interfered with implant survival.
Since this systematic review was not registered in any database, the protocol is not avail-
able on a website.
4
Table 2. PRISMA checklist.
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7    information 
sources
Electronic literature databases (PubMed/Medline, Embase) were used exclusively.
Search period 1980 up to March 2018 (limit set by most recent available publication). Last 
search date August 2018.
4
8    search See Table 1
9    study 
      selection
All publications identified with MESH- and search term combinations were screened 
independently if meeting the scope and inclusion criteria and eligible publications were 
further screened regarding the abstracts by two independent reviewers. Publications were 
included into systematic review after full-text analysis, if all data required were provided. 
Discrepancies between selected publications due to reviewers´ choice were discussed and 
full agreement was reached. See Figure 1.
4
10 data 
      collection 
      process
All data required were retrieved from publications into tables, considering pathologic 
conditions oLp, Pe, EB, SjS, sLE, sSc.
Since data were provided within the publications, no contact to authors / investigators was 
sought.
4
11 data items number of patients / implants, patients áge, gender, observational period, implant survival 
rate
4
12 risk of bias 
      in individual 
      studies
A quality assessment of the publications included for the systematic review following the 
Cochrane collaboration recommendations for evaluation of RCTs (Higgins JPT, Green S. 
Cochrane Handbook for Systematic Reviews of Interventions. 2011. Versión 5.1.0. http://
handbook.cochrane.org/) was not applicable due to the entity of included publications 
(especially the criteria random sequence generation and allocation concealment (both 
accounting for selection bias), blinding of participants and personnel (performance bias), 
blinding of outcome assessment (detection bias) were not applicable, since most publica-
tions were case reports or case series. Due to selective reporting within case reports, at-




      measures
Weighed mean values of patient-related implant survival rate and observational periods 
were calculated.
4
14 synthesis of 
     results
Meta-analysis was calculated regarding incidence rate referring to mean number of im-
plant failures per year.
4
15 risk of bias 
      across  
      studies
Due to the publications´ entities (most of them were case reports, only two studies pro-
vided with a control group of healthy patients), the risk of bias was considered high.




      analyses 
Comparison of survival rates were performed utilizing t-test following confirmation of 
normal distribution (Kolmogorov-Smirnow-test) for patients with oLp.
5-6
17 results
      study 
      selection
Numbers of studies identified for each pathologic condition and numbers of studies in-
cluded are reported within the text.
5-6
18 study 
   characteristics
See Table 3 sections a-d 5-6
19 risk of bias 
within studies
Funnel plot analysis revealed four studies with extremely outlying data, which were ex-
cluded from further meta-analysis (figures 2a and b).
7
20 results of 
individual 
      studies
See table 3, sections a-d. 5-6
21 synthesis of 
results
See Figures 3a-d. 7
22 risk of bias 
across  studies
See figures 2a-b. 7
Table 2 continue. PRISMA checklist.




See Table 3. 5-6
24 summary of 
evidence
On basis of weak-evidence publications with a high risk of bias, implant survival rates 
of patients with oLp, Pe, EB, SjS, sLE or sSc are comparable to those of healthy patients. 
Mean follow-up periods were exceeding 32 months.
Further case studies or prospective studies should report outcomes following longer ob-
servation periods with consideration of course of the diseases. Multicentric data analyses 
might be a viable method to gain more data regarding the above mentioned diseases, since 
the prevalence of the diseases is low.
11
25 limitations Since most of included publications were low-level evidence case reports or case series, 
and mean follow-up was calculated between 32 and 45 months, conclusions can be drawn 
on a very limited evidence-level.  Risk of attrition bias and reporting bias are supposed 
high.
26 conclusions Within the limits of low-level evidence publications analysed and limited mean observa-
tional periods, implant-prosthetic treatment of patients with oLp, Pe, EB, or SjS seems 
to be a promising treatment option. For implant-prosthetic rehabilitation of patients with 
Pe and sLE no conclusions can be drawn due to lack of sufficient clinical data. However, 
treatment guidelines regarding healthy patients should be strictly followed. Moreover, 
frequent recall is recommended in patients affected with oLp, SjS, EB, SSc, Pe or sLE.
11
27 funding No funding nor other financial nor other support was received by any author with regard to 
this systematic review. All authors declare no conflict of interests.
1
Table 2 continue-1. PRISMA checklist.
Results
Figure 1 displays search results, identification, screen-
ing for eligibility and inclusion of publications consid-
ered for systematic review and meta-analysis. Compari-
son of inclusion of publications considering abstract 
analysis revealed a kappa-value of 0.932 (p < 0.0001). 
Disagreement regarding inclusion of two and exclusion 
of one publications was resolved after full text analysis, 
finally reaching full agreement.
The risk of bias assessment of included publications re-
vealed an overall high risk of attrition bias and reporting 
bias, since case reports and case studies were included 
mainly. Assessment of random sequence generation, al-
location concealment, blinding of participants as well 
as outcome assessment (accounting for selection bias, 
performance bias and detection bias) was not applicable. 
Data were retrieved from included publications and in-
formation on reference, study type, number of implants 
and patients and their age, duration of follow-up period 
as well as implant survival rates are listed in Table 3, 3 
continue sections a to d.
-Oral Lichen planus
Nine out of 32 publications identified within databases 
met the inclusion criteria (four case reports, three ret-
rospective studies, one prospective study, and one pro-
spective controlled study). Data of 73 female and 27 
male patients suffering from oLp were retrieved from 
these nine publications (see Table 3 section a). From the 
case report by Reichart (6) one patient was discarded 
due to unknown duration of follow-up period. 
Despite lack of details regarding prosthodontic treat-
ment for patient- or implant-based analysis in some 
publications (information on 38 % of patients as well 
as 37.8 % of implants were not available), the majority 
of patients (90.3 %) and implants (91.6 %) respectively 
were treated with fixed partial dentures, whereas only a 
few removable complete prostheses (1.6 % by patient-
related and 2.1 % by implant-related analysis) and fixed 
complete prostheses (8.1 % by patient-related and 6.3 % 
by implant-related analysis) were used. 
In one study, 55 implants were inserted during acute 
flare of active oLp using immediate implantation into 
the socket subsequently following extraction (17 im-
plants) or immediate loading mode (31 implants), or 
both conditions (9 implants). 42 implants failed (24 im-
mediately loaded, 6 immediately inserted) and were 
removed and replaced after oral corticosteroid therapy. 
None of the replaced implants failed (10). 
In the study by Anitua et al. (11), short implants up to 
8.5 mm in length were used exclusively in 8 patients 
with erosive and 15 patients with reticular oLp.
-Sjögren ś Syndrome
Nine publications of 13 identified within the databases 
met the inclusion criteria for the systematic review and 
revealed data of 65 female as well as 6 male patients 
suffering from SjS, receiving implant-prosthetic reha-
bilitation (six case reports and one case series, retro-
spective and prospective study, each, see Table 3 sec-
tion b). Data regarding distribution of type of prosthesis 
were available related to jaw (maxilla and or mandible) 
only. 92 jaws were treated. Of these, 44.6 % were treat-
ed using implant-retained removable complete dentures 
(overdentures). While counting implant-fixed single 
crowns (29.3 %) and fixed partial dentures (7.6 %) for 




records identified through electronic database searching (after removing 
duplicates) 
oLP               SjS               EB               sSc               Pe               sLE                    
























oLP               SjS               EB               sSc               Pe               sLE                   
n=32             n=13           n=16             n=16             n=7             n=8                                  
records excluded 
n=20             n=4             n=4                n=6               n=6              n=7                                                
full-text articles assessed for eligibility 
oLP               SjS               EB               sSc               Pe               sLE                   
n=12             n=10            n=12            n=10             n=1             n=1                               
Full-text article excluded for not fulfilling the inclusion criteria 
n=3               n=1                                  n=4 
publications included for quantitative synthesis 
oLP               SjS               EB               sSc               Pe               sLE                   
n=9               n=9              n=12            n=6              n=1              n=1                                
Fig. 1. Search results, identification, screening for eligibility and inclusion of publica-
tions considered for systematic review and meta-analysis.
fixed partial restorations (36.9 %) and counting 18.5 % 
fixed complete dentures, more jaws were treated using 
fixed restorations on implants (55.4 %) compared to re-
movable prostheses.
-Epidermolysis bullosa
Data from 12 publications regarding implant-prosthetic 
rehabilitation of 27 patients (10 male and 17 female pa-
tients) with EB, receiving 152 implants were analysed 
(see Table 3, 3 continue section c). From the case series 
by Peñarrocha et al. (23) three patients with 27 implants 
were discarded since these were also subject of another 
publication (22). 
Analysis by jaw (n = 41) revealed, that the majority of 
jaws were treated with implant-fixed complete dentures 
(70.7 %), whereas 22 % of jaws were treated with im-
plant-retained removable complete dentures and 7.3 % 
with implant-fixed partial dentures.
-Systemic Sclerosis
Six publications out of 16 matching the search term 
combinations met the inclusion criteria, reported on 
treatment courses of one male and five female patients 
with sSc undergoing implant-prosthodontic rehabili-
tation (data listed in Table 3, 3 continue section d). 
Analysis per jaw revealed the use of four implant-fixed 
complete dentures, two implant-borne bar-retained re-
movable complete dentures and three implant-fixed par-
tial dentures (two were integrated in one maxilla). 
-Pemphigus and systemic Lupus erythematosus
Of seven publications on Pe and eight publications on 
sLE identified, one publication was included each, re-
porting on one female patient (70 years old) suffering 
from Pe (2 implants, ball-attachment-retained man-
dibular overdenture, 32 months observational period) 
(36) and one female patient with sLE (49 years old, 6 
implants, single fixed crowns, 24 months observational 
period) (37), both with 100 % implant survival. 
-Meta-analyses
Meta-analysis was carried out, calculating a funnel plot 
to detect publication bias. 
The funnel plot for all publications indicated that four 
publications (3,10 [including results prior to corticoste-
roid therapy in “active” oLP only],11,13) had to be ex-
cluded because their rate estimates for implant failure 
were too extreme (outliers) (see Figure 2a). Figure 2b 
shows the funnel plot, showing no asymmetry, reveal-
ing no evidence for further bias after removing the four 

















section a  oLp
Esposito et al. 2000 (3) cr 1 2 69 32, 60 0
Esposito et al. 2003 (4) cr 2 4 72, 78 21 100
Öczakir et al. 2005 (5) cr 1 4 74 72 100
Reichart 2006 (6) cr 2 5 63, 68 36, 156 100
Hernandez et al. 2012 (7) pc 18 56 53.7 56.5 100
Czerninsky et al. 2013 (8) r 14 54 59 12 100
Lopez-Jornet et al. 2014 (9) r 16 56 64.5 42 96.4








Anitua et al. 2018 (11) r 23 66 58 68 98.5
total
weighed mean




remarks *calculated considering the results following corticosteroid therapy (10)
section b   SjS
Payne et al. 1997 (12) cr 3 26 38, 38, 40 96, 36, 18 88.5
Isidor et al. 1999 (13) p 8 54 53 - 70 48 87
Binon 2005 (14) cr 1 6 67 156 100
Öczakir et al. 2005 (5) cr 2 12 63, 64 24, 60 100
Weinländer et al. 2010 (15) cs 4 21 55.6 42, 46, 48, 91 100
Spinato et al. 2010 (16) cr 1 6 62 22 100
de Mendonça Invernici et 
al. 2014 (17)
cr 1 2 58 72 100
Korfage et al. 2016 (18) r 50 140 67 42 97.1




64.2 ± 6.9 45.2 ± 23.8 94.2 ± 23.4
section c  EB
Peñarrocha-Diago et al. 
2000 (20)
cr 4 15 35, 30, 26, 30 12, 24, 36, 48 100
Lee et al. 2007 (21) cr 1 8 29 23 100
Peñarrocha et al. 2007a (22) cr 3 27 44, 29, 43 60, 36, 12 96.2
Peñarrocha et al. 2007b 
(23) 
cs 3 11
23, 36, 28, 44, 
29, 43
108, 96, 84, 60, 
36, 12
97.4
Larrazabal-Moron et al. 
2009 (24)
cr 1 2 52 18 100
Oliveira et al. 2010 (25) cr 1 2 13 48 100
Müller et al. 2010 (26) cr 1 10 >20 48 100
Table 3. Study type, demographic data, duration of observation periods and implant survival rate of patients with oLp (section a), SjS (section 
b), EB (section c), sSc (section d).
Med Oral Patol Oral Cir Bucal. 2019 Mar 1;24 (2):e217-30.                                                                   Implants in patients with oral manifestations of autoimmune or muco-cutaneous diseases
e225
Peñarrocha-Oltra et al. 2011 
(27)
cs 6 32
24, 34, 55, 51, 
33, 27
24, 36, 12, 24, 
12, 48
100
Peñarrocha-Oltra et al. 
2012 (28)
cs 4 23 27, 55, 51, 44 24, 12, 48, 24 100
Augustin-Panadero et al. 
2015 (29)
cr 1 8 19 18 87.5
Augustin-Panadero et al. 
2017 (30)
cr 1 6 52 30.7 100




35.4 ± 11.6 32.6 ± 22.2 98.7 ± 11.3
section d sSc
Jensen & Sindet-Pedersen 
1990 (32)
cr 1 9 39 24 88.9
Raviv et al. 1996 (33) cr 1 3 65 28 100
Öczakir et al. 2005 (5) cr 1 8 64 60 100
Weinländer et al. 2010 (15) cr 1 6 55.6 46 100
Zigdon et al. 2011 (34) cr 1 12 45 36 100




54.9 ± 10.7 37.5 ± 13.4 97.7 ± 15.1
Table 3 continue. Study type, demographic data, duration of observation periods and implant survival rate of patients with oLp (section a), SjS 
(section b), EB (section c), sSc (section d)
Fig. 2. a) Funnel plot for all publications. Four publications (3,10 [including results prior to corticosteroid therapy in “active” 
oLP only],11,13) were found to reveal too extreme rate estimates for implant failure. b) Funnel plot for all publications following 
exclusion of outliers (3,10 [including results prior to corticosteroid therapy in “active” oLP only],11,13), revealing no risk of bias. 
publications as indicated. Thus, the remaining publica-
tions were included into further meta-analysis. 
Figure 3 shows the forest plot for all included publica-
tions (n=35) on oLp, SjS, EB, sSc, Pe, and sLe  revealing 
a considerably low incidence rate referring to mean num-
ber of implant failures per year of 0.0297 (fixed effect 
model). Figures 3a-d show forest plots for data, retrieved 
from publications on oLp, SjS, EB, and sSc, exclusively. 
a b
(cr case report, cs case series, p prospective study, pc  prospective controlled study, r  retrospective study).
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Fig. 3. a) Forest plot for 7 publications on oLp. Incidence rate of mean number of implant failures per year: 0.0217 
(CI95%: 0.0090; 0.0520, fixed effect model), no significant heterogeneity: I2=6.6% (CI95%: 0.0%; 72.7%); p=0.38.b) 
Forest plot for 8 publications on SjS. Incidence rate of mean number of implant failures per year: 0.0250 (CI95%: 0.0135; 
0.0465, fixed effect model), no significant heterogeneity: I2=10.4% (CI95%: 0.0%; 70.9%); p=0.35. c) Forest plot for 12 
publications on EB. Incidence rate of mean number of implant failures per year: 0.0407 (CI95%: 0.0199; 0.0833, fixed 
effect model), no significant heterogeneity: I2=0.0% (CI95%: 0.0%; 0.0%); p=0.98. d) Forest plot for 6 publications on 
sSc. Incidence rate of mean number of implant failures per year: 0.0310 (CI95%: 0.0109; 0.0885, fixed effect model), no 
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Furthermore, measures for heterogeneity I2 for all includ-
ed studies and for the subgroups regarding oLp, SjS, EB, 
sSc, Pe, and sLe were calculated. In all instances I2 was 
small and not significantly different from zero.
Discussion
Gingiva and other oral tissues may exhibit several 
pathologic phenomena as symptoms or manifestations 
of systemic diseases, requiring further diagnostic and 
interdisciplinary treatment (38). Although epidemiolog-
ical data indicate low prevalence with regional varia-
tions for oLp (1 – 2 % (39)), SjS (0.5 – 1 % (40)), and 
sLe (0.05 % (41)), or rare prevalence for EB (up to 0.001 
% (42)), sSc (up to 0.03 % (43)), and Pe (0.05 % (44)), 
these patients affected require dental treatment, includ-
ing prosthetic rehabilitation. Oral conditions in auto-
inflammatory, autoimmune, rheumatic or muco-cuta-
neous diseases require special care due to oral lesions 
(ulcer- or blister formation, enhanced risk for malig-
nant tumours), sicca symptoms, scar tissue formation, 
limited mouth opening, and due to side effects of anti-
inflammatory, immune-modulating medication. Con-
sequently, quality of life of these patients is reduced. 
Burden related to disease as well as adverse effects of 
medications is high for the patients, challenging the 
dental professional due to limited treatment options re-
garding conventional prosthodontic therapy. Especially 
wearing mucosal-borne removable partial or complete 
prostheses is impeded if not impossible.
Decision-making for dental implant-retained or fixed 
prosthodontic devices in order to improve speaking, swal-
lowing, chewing, quality of life (45) should consider a 
critical weighing of advantages and risks, comorbidities as 
well as disease-related medication adverse effects, possibly 
interacting with osseointegration and implant prognosis. 
Generally, in patients affected by conditions and diseases 
mentioned above, large-area contact between oral mucosa 
and artificial surface of prosthodontic device and retention 
of the total or partial denture, or reduction of contact area 
between prostheses and mucosa is pursued.
The numbers of publications regarding implant-prosth-
odontic treatment under the above mentioned conditions 
and pathoses are low in general. The evidence-level of 
38 publications included into this systematic review 
was limited (among them 26 case reports, four case se-
ries, four retrospective studies, two prospective studies, 
one prospective controlled study). Therefore, decision 
making prior to any intervention is based on low level 
of external evidence, but should include knowledge, 
experience and internal evidence of the dentist as well 
as thorough analysis of any conditions of the individual 
patient to evaluate risks and expected benefit and to pro-
vide a thorough patient information. Interdisciplinary 
consultations are required. Status of disease progress 
and overall prognosis should be considered additionally. 
-Oral Lichen planus
oLp is a chronic autoimmune and inflammatory disease 
and may manifest as asymptomatic or symptomatic. 
About 1/3 of affected patients reveal gingival mani-
festations. Patients complain about mucosal burning 
sensations or pain caused by epithelial desquamation, 
erosions and ulcerations. Therefore, any contact or fric-
tion between dentures and mucosa should be avoided 
or reduced.
Data analysis of 100 patients included into this sys-
tematic review showed, that implant-fixed partial as 
well as complete prostheses were utilized mainly for 
prosthodontic rehabilitation of patients suffering from 
oLp. Implant-retained removable complete dentures 
were used in only 1.6 % of patients. Considering those 
patients with active oLp and replacement of failed im-
plants following systemic corticosteroid therapy in one 
study (10), weighed mean implant survival rate was 
calculated 98 % after a mean follow-up period of 44.6 
months, which is comparable to data from healthy pa-
tients.     
Implants in patients with erosive oLp revealed no sig-
nificant reduction of survival in some publications (4,6-
9,11), whereas Aboushelib et al. (10) reported a signifi-
cant effect of “active” oLp on implant loss, especially 
for those immediately loaded. Following oral cortico-
steroid and local soft laser therapy and recovery, implant 
replacement was performed and no further implant fail-
ures were observed. Therefore, to prevent disturbance 
of wound healing or osseointegration it is recommended 
to omit any surgical intervention during active, erosive 
phases of oLp (3,6-8,10). Additionally, local treatment 
of erosions and ulcerations with clobetasoldipropionate 
is recommended (7). Strict patient adherence to regular 
and frequent follow-up appointments and oral hygiene 
instructions should be asserted not only to rule out in-
flammatory tissue response interfering with long-term 
survival of implants (peri-implant mucositis and peri-
implantitis) (1), but also to early detect malignant trans-
formation of oLp into OSCC. 
-Sjögren’s Syndrome
Treatment courses of 71 patients suffering from SjS with 
a weighed mean age 64 years were published – female 
patients were treated predominantly. Within this sys-
tematic review, the weighed mean survival of implants 
of 94 % after a mean follow-up of 45 months was found 
slightly less regarding other autoimmune diseases con-
sidered within this systematic review. 
SjS is a chronic systemic autoimmune disease. Due to 
affection of exocrine glands – salivary and lacrimal 
glands in particular – patients suffer from hyposaliva-
tion and xerophthalmia, resulting – among other bur-
dens – in stomatitis sicca, xerostomia, burning sensa-
tions, and difficulties to swallow.  
Prosthodontic rehabilitation – especially using mucosal-
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borne dentures – is impeded due to dryness of oral mu-
cosa, causing mucosal sensations, pain, or ulcerations. 
However, within the cohort of published treatment 
courses included into this systematic review, nearly half 
of the jaws (44.6 %) were treated using implant-retained 
removable complete dentures, whereas 55.4 % of the 
jaws were treated with implant-fixed prosthodontic res-
torations.
Although biofilm accumulation with concomitant en-
hanced risk of peri-implant mucositis or peri-implantitis 
is suspected due to hyposalivation, relatively high mean 
weighed implant survival rate was found in patients 
with SjS. 
Patients with secondary SjS and rheumatoid arthritis 
sometimes may reveal limited manual abilities to per-
form proper oral hygiene. This and possible necessity 
of anti-inflammatory as well as immunosuppressive 
medication possibly interfering not only with osseointe-
gration but health of peri-implant tissue should be con-
sidered while risk-benefit assessment, in therapy plan-
ning and thorough patient information as well. Patients 
should follow regular and frequent recall to early detect 
peri-implant mucositis and indicators for oral hygiene 
deficit.
-Epidermolysis bullosa
EB as a rare, inherited, recessive disease of skin and 
mucosa, manifests by forming of trauma-induced bul-
lae – often with subsequent scar formation – and pseu-
dosyndactyly. Involvement of oral and gastrointestinal 
mucosa include recurrent bullae, scar formation, mi-
crostomia and ankyloglossum, shallow vestibular sulci, 
but also periodontitis, alveolar bone resorption with at-
rophy of the edentulous areas of maxilla and mandible 
– all interfering with conventional prosthodontic treat-
ment - and enhanced predisposition for oral squamous 
cell carcinoma (46). 
Data analyses of 27 patients (mean age 35 years) re-
vealed a weighed mean implant survival rate of 98.7 
% after a mean observation period of 33 months. More 
than 80 % of the jaws were treated with implant-fixed 
complete or partial dentures, whereas nearly 20 % of 
the jaws were treated with implant-retained remov-
able overdentures with short dental arch rehabilitation 
to prevent impeded oral hygiene access due to limited 
posterior space and mouth opening.   
-Systemic Sclerosis
SSc is an autoimmune multisystem rheumatic disease 
affecting connective tissue, and an inflammatory, vas-
cular and sclerotic disease of the skin as well as of or-
gans (lung, heart, gastrointestinal tract). Oral and facial 
clinical findings are mask-like face, thin vermilion bor-
der, radial perioral furrows, microstomia, sclerosis of 
the tongue-tie and induration of the tongue. Hyposali-
vation, microstomia, ankyloglossia, limited mouth 
opening but also minor manual skills interfere with oral 
hygiene ability. While providing with implant-fixed 
prosthodontic superstructures, reconstructing short-
ened dental arches, disadvantages of lack of removal 
of overdentures due to progression of losing manual 
dexterity and microstomia might be taken into account 
(47,48). Close cooperation between dental professionals 
and rheumatologists is necessary for decision making, 
in treatment planning and maintenance.   
Data on dental implant treatment courses of six patients 
suffering from sSc were available from 6 case reports, 
revealing a weighed mean implant survival rate of 97.7 
% after a mean observation period of 37.5 months. 
Implant-fixed complete or partial dentures were used 
mainly and two patients received implant-retained re-
movable overdentures. 
-Pemphigus and systemic Lupus Erythematosus
Pe is an autoimmune mucocutaneous disease, charac-
terized by epithelial blistering at skin and mucosa, leav-
ing erosions or ulcers following rupturing affecting not 
only the oral cavity but also the mucosa of nose, con-
junctivae, genitals, esophagus, pharynx and larynx. 
SLE is a multisystem autoimmune disease with con-
nective tissue and blood vessel disorder, characterized 
by episodes of recurrent acute or chronic inflammation 
with intermediate phases of remission, mainly affecting 
joints, internal organs and skin. Oral manifestations are 
common – especially during disease flares – and pres-
ent as forms of painless ulcers (49). Treatment of both 
Pe and sLE comprises immunosuppressant medications 
mainly, which may cause adverse effects (among them 
candida-infections of the oral mucosa) with individu-
ally different degree of affection, and dependent on dos-
age and duration of use. As usual in dental treatment of 
special needs patients or patients with systemic autoim-
mune or mucocutaneous diseases, close cooperation of 
the dentist and the treating specialists is mandatory. 
Limited mouth opening and hyposalivation due to sec-
ondary Sjögren’s syndrome as associated co-morbidi-
ty (50) can interfere with wearing of mucosal-borne 
dentures. Since ill-fitting prostheses or any traumatic 
contact with the mucosa can cause formation of vesicu-
lobullous or ulcerative lesions, implant-borne stabiliza-
tion of dentures will result in less trauma and higher 
patient comfort (36,37).  
Only two case reports were found with data on one fe-
male patient each with Pe and sLE, both revealing 100 
% implant survival after a follow-up period of at least 
24 months, which is too less data to offer any recom-
mendations. However, patients with Pe or sLE seem to 
benefit from implant-retained or implant-fixed prosth-
odontic treatment.   
Conclusions
Guidelines regarding implant treatment of patients with 
oLp, Pe, EB, SjS, sLE or sSc do not exist so far. Results 
Med Oral Patol Oral Cir Bucal. 2019 Mar 1;24 (2):e217-30.                                                                   Implants in patients with oral manifestations of autoimmune or muco-cutaneous diseases
e229
of mainly low-evidence publications demonstrate en-
couraging outcomes regarding dental implant survival, 
which are comparable to those of healthy patients.  Pa-
tients with the above mentioned diseases seem to ben-
efit from implant-retained or implant-fixed prostheses. 
Disease-related contraindicating conditions cannot be 
defined.
However, for implant-prosthetic rehabilitation of pa-
tients with Pe and sLE no conclusions can be drawn due 
to lack of sufficient clinical data. 
Implant-prosthetic treatment guidelines regarding 
healthy patients should be strictly followed,  close recall 
intervals and full therapy adherence by the patients is 
required, and close cooperation of the dental profession-
al and the treating specialists is mandatory in patients 
affected with  oLp, Pe, EB, SjS, sLE or sSc. 
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